Primary biliary cirrhosis is a chronic, autoimmune liver disease characterized by non-suppurative destructive cholangitis and highly specific auto-antibodies to pyruvate dehydrogenase complex (PDC)[@R1]. It is an important cause of chronic liver disease and a well-established indication for liver transplantation. In the UK, the prevalence of PBC is approximately 35 per 100,000 adults and 94 per 100,000 women aged 40 years or older[@R2]. PBC has a sibling relative risk of \~10, suggesting a substantial genetic contribution to PBC[@R3].

Previous studies have established that PBC is associated with *HLA-DR8*, with odds ratio ranging from 2.4 to 3.3 depending on the population examined[@R4]. To date, six non-*HLA* loci have been associated with PBC at a genome-wide level of significance (P\<5×10^−8^): *IL12A* (3q25)[@R5], *IL12RB2* (1p31)[@R5], *IRF5/TNPO3* (7q32)[@R6],[@R7], *ORMDL3/IKZF3* (17q12)[@R6],[@R7], *MMEL1* (1p36)[@R6], and *SPIB* (19q13)[@R7]. To identify additional PBC risk loci we conducted a GWAS in a large cohort of UK PBC cases and population controls as part of the Wellcome Trust Case Control Consortium 3.

PBC cases were drawn from the UK PBC Consortium, which consists of 142 NHS Trusts in the UK, including all liver transplant centers. All cases were of self-declared British or Irish ancestry. PBC cases were genotyped using the Illumina 660W-Quad array. UK population controls were genotyped using the Illumina Human1M-Duo by the Wellcome Trust Case Control Consortium 2 and consisted of individuals from the 1958 British Birth Cohort and National Blood Service[@R8]. Following stringent quality control (see [Online Methods](#SD2){ref-type="supplementary-material"}), 507,467 SNPs were available across 1,840 cases and 5,163 'historical' population controls (see [Supplementary Tables 1](#SD1){ref-type="supplementary-material"} and [2](#SD1){ref-type="supplementary-material"}). The quantile-quantile plot of the case-control chi-square test statistics demonstrates a substantial excess of significant associations in the tail of the distribution, even after removal of known loci, which cannot be ascribed to overall inflation of the distribution (genomic control λ=1.09; see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

We identified 34 loci where one or more SNPs showed at least suggestive evidence for association (P\<1×10^−5^), including six of the seven previously associated loci ([Table 1](#T1){ref-type="table"}). We found weaker evidence for replication at the seventh previously associated locus 1p36 (containing *MMEL1*; P=4×10^−3^). 28 loci achieving at least suggestive significance and not previously associated with PBC at genome-wide significance were followed up by genotyping 46 SNPs in an independent panel of 620 cases from the UK PBC Consortium ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). A comparison set of 2,514 'historical' UK population controls previously genotyped by TwinsUK using the Illumina HumanHap610 array was obtained (see [Online Methods](#SD2){ref-type="supplementary-material"}). Twelve of these 28 loci were significant at P\<0.05 in the replication study, and P\<5×10^−8^ in the combined analysis of the discovery and replication cohorts, and thus represent novel PBC associations ([Table 2](#T2){ref-type="table"}). Two of these loci (2q32 and 1q31) showed suggestive evidence of association in a previous PBC GWAS study[@R5]. Follow-up genotyping in large independent panels of cases and controls from a range of ethnicities is needed to further characterize these loci.

To identify additional risk loci, we combined summary statistics from our discovery cohort with those from the two datasets included in the previously published meta-analysis of PBC GWAS[@R7]. Three further novel loci reached genome-wide significance (see [Table 3](#T3){ref-type="table"}). This included one locus (14q32) that just failed to achieve genome-wide significance in our combined analysis of discovery and replication cohorts (P = 1.69×10^−7^), but did so with the addition of data from the study by Liu et al.[@R7] (P = 2.61×10^−13^). As SNPs at the two other loci (3p24, 11q13) were not genotyped in our replication cohort, and the loci were identified based on summary statistics alone, genotyping using an independent technology in additional cohorts is needed to fully validate these associations. A combined GWAS meta-analysis is still warranted because we were only able to meta-analyze the top 100 SNPs from the Liu et al. study. Genome-wide imputation using HapMap3 reference panels did not identify any further genome-wide significant loci (see [Online Methods](#SD2){ref-type="supplementary-material"}, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}, and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}), although for some loci imputed SNPs provided stronger evidence of association than the genotyped SNPs. No statistically significant gene-gene interactions were detected between associated loci, or after fitting an *HLA*-risk model (see [Online Methods](#SD2){ref-type="supplementary-material"} and [Supplementary Table 5](#SD1){ref-type="supplementary-material"}).

We found evidence for a second independent association at the 3q25 locus containing *IL12A* and *SCHIP1*, as did Liu et al[@R7] (see [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Three SNPs, located between *IL12A* and *SCHIP1*, remained genome-wide significant following a conditional logistic regression adjusting for the most significant SNP in the region (rs485499). Conducting the same analysis using the imputed data identified a further two SNPs reaching genome-wide significance. These five SNPs are all in linkage disequilibrium (LD; r^2^\>0.2) with each other, but none are in LD with rs485499. They are located downstream of *SCHIP1*, but upstream of *IL12A* (see [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Fine mapping of this locus is needed to determine whether these association signals implicate independent variants affecting the same gene, or two different genes.

We identified plausible candidate genes within associated loci via manual curation, supported by evidence from: a) previous GWAS findings for other autoimmune diseases; b) GRAIL[@R9], a literature-mining tool that identifies non-random, evidence-based links between genes; c) identification of non-synonymous SNPs in 1000 genomes data that are in LD (r^2^\>0.8) with the most associated genotyped SNP in each locus; d) identification of eQTL within associated loci that are in LD (r^2^\>0.8) with the most associated SNP at that locus, using data from Dixon et al.[@R10] (see [Online Methods](#SD2){ref-type="supplementary-material"} and [Supplementary Tables 7](#SD1){ref-type="supplementary-material"}-[10](#SD1){ref-type="supplementary-material"}). Even in aggregate these analyses do not identify the gene(s) containing causal variants but they allow us to identify potential candidate genes for future follow-up studies. [Supplementary Figure 4](#SD1){ref-type="supplementary-material"} shows all genes within each of the associated loci.

The results from the GWAS of PBC conducted to date provide additional support for the involvement of three pathways previously implicated in the pathogenesis of PBC: NF-κB signaling, T-cell differentiation, and Toll-like receptor (TLR) and Tumor Necrosis Factor (TNF) signaling.

We identified several loci containing genes involved in activation of NF-κB, a transcription factor which regulates expression of many genes involved in the immune response and is highly activated in other autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, and asthma[@R11]. Its importance in PBC is suggested by evidence that NF-κB modulates the balance of survival and apoptosis in activated hepatic stellate cells[@R12], and NF-κB p50 −/− mice show aggressive hepatic inflammation and fibrosis[@R13]. The locus we identified at 4q24 contains the *NFKB1* gene itself, and we identified genes in pathways leading to NF-κB activation at four other loci: 22q13 (*TAB1*), 12p13 (*TNFRSF1A*), 3q13 (*CD80*), and 11q13 (*RPS6KA4*).

Loci identified to date suggest a role for T-lymphocyte differentiation in the development of PBC. T~H~1 immune responses have been implicated in many autoimmune diseases[@R14] and may be involved in development of autoreactive T-cells, consistent with the putative role of PDC-specific autoreactive T~H~1 cells in the pathogenesis of human PBC and animal disease models[@R15]. IL-12 signaling promotes T~H~1-type immune responses by driving differentiation of activated, naïve T-cells to T~H~1 cells[@R16] and three loci containing genes involved in IL-12 signaling have been identified for PBC: 3q25 (*IL12A*) and 1p31 (*IL12RB2*) by Hirschfield et al.[@R5], and 2q32 (*STAT4*) in this study. These results provide further support for the T~H~1 hypothesis regarding PBC development.

Activation of TLR signaling, and its downstream effectors such as TNFα, is well described in PBC[@R17]. The 7q32 locus, identified by Liu et al.[@R7], contains *IRF5* which is activated in response to TLR-signaling and leads to selective expression of TNFα. We identified a locus at 11q13 containing *RPS6KA4*, which suppresses TLR-dependent cytokine production[@R18]. TNFα is an activating factor for a number of intracellular pathways that determine the fate of hepatocytes, and thus plays a key role in liver homeostasis[@R19]. We identified three loci containing genes in TNFα signaling pathways: 12p13 (*TNFRSF1A*), 1q31 (*DENND1B*), and 14q32 (*TNFAIP2*). *TNFRSF1A* is one of two receptors for TNFα, and *TNFRSF1A* −/− mice show attenuated liver fibrosis when compared to wild-type mice after administration of a potent hepatotoxin[@R20]. *DENND1B* interacts directly with *TNFRSF1A*[@R21] and has previously been associated with asthma[@R22]. TNFα signaling also directly induces *TNFAIP2* expression[@R23].

In summary, this is the first report in a new series of GWAS undertaken by the WTCCC3. Twelve novel PBC risk loci have been identified in this study of \>7,000 European samples, making this the largest GWAS of PBC to date. In addition, a further three loci achieve genome-wide significance following meta-analysis with published data. For many of the associated loci we have identified plausible candidate genes that support the involvement of the innate and adaptive immune systems in PBC etiology, particularly signaling via the NF-κB, TLR, and TNF pathways, although these findings require confirmation through fine-mapping, gene-expression and functional studies.
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###### 

Association results and *in silico* analyses for the 7 previously confirmed primary biliary cirrhosis risk loci.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CHR     SNP          RISK\    LEFT/RIGHT REGION\   CANDIDATE GENE[a](#TFN1){ref-type="table-fn"}\   AI[b](#TFN2){ref-type="table-fn"}   nsSNP[c](#TFN3){ref-type="table-fn"}   GWAS Cohort                          
                       ALLELE   (MB)                 (Number of genes in region)                                                                                                                                      
  ------- ------------ -------- -------------------- ------------------------------------------------ ----------------------------------- -------------------------------------- ------------- ------- -------------- ----------------
  1p36    rs10752747   T        2.39 - 2.78          *MMEL1* (6)                                      ○                                                                          0.339         0.367   2.65×10^−3^    1.13\
                                                                                                                                                                                                                      (1.04 - 1.22)

  1p31    rs17129789   C        67.53 -- 67.71       *IL12RB2* (2)                                    ○                                                                          0.177         0.247   9.48×10^−20^   1.52\
                                                                                                                                                                                                                      (1.39 - 1.67)

  3q25    rs485499     T        160.96 - 161.3       *IL12A* (2)                                      ●                                                                          0.574         0.651   2.29×10^−16^   1.38\
                                                                                                                                                                                                                      (1.28 - 1.50)

  6p21    rs7774434    C        26.21 - 33.74        Many (*MHC*)                                     ○                                   ●                                      0.379         0.494   3.86×10^−34^   1.60\
                                                                                                                                                                                                                      (1.48 - 1.73)

  7q32    rs12531711   G        128.33 - 128.57      *IRF5* (2)                                       ●                                                                          0.107         0.159   8.90×10^−17^   1.58\
                                                                                                                                                                                                                      (1.41 - 1.76)

  17q12   rs7208487    T        34.61 - 35.49        *ORMDL3* (23)                                    ●                                                                          0.840         0.874   7.89×10^−7^    1.32\
                                                                                                                                                                                                                      (1.18 - 1.48)

  19q13   rs3745516    A        55.52 - 55.73        *SPIB* (11)                                                                          ●                                      0.226         0.287   1.63×10^−13^   1.38\
                                                                                                                                                                                                                      (1.32 -- 1.44)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The putative candidate gene represents the strongest candidate within the region based on available evidence, but does not preclude the existence of other plausible candidate genes within the region. The number of genes is based upon the RefSeq gene track.

Open circles indicate the locus has been previously associated with another autoimmune disease; a filled circle indicates the same candidate gene has also been suggested.

Filled circles indicate a non-synonymous SNP in LD with our top SNP was identified in the candidate gene.

RAF indicates the risk allele frequency.

###### 

Association results and *in silico* analyses for 12 newly confirmed primary biliary cirrhosis risk loci.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CHR     SNP          RISK\    LEFT/RIGHT\       CANDIDATE\                             AI[b](#TFN7){ref-type="table-fn"}   GRAIL[c](#TFN8){ref-type="table-fn"}   nsSNP[d](#TFN9){ref-type="table-fn"}   GWAS cohort   Replication cohort   Combined samples                                                                                
                       ALLELE   REGION (MB)       GENE[a](#TFN6){ref-type="table-fn"}\                                                                                                                                                                                                                                                        
                                                  (Number of\                                                                                                                                                                                                                                                                                 
                                                  genes in region)                                                                                                                                                                                                                                                                            
  ------- ------------ -------- ----------------- -------------------------------------- ----------------------------------- -------------------------------------- -------------------------------------- ------------- -------------------- ------------------ --------------- ------- ------- ------------- --------------- -------------- ---------------
  1q31    rs12134279   T        195.58 - 196.21   *DENND1B* (4)                          ○                                   ●                                                                             0.202         0.250                1.07×10^−9^        1.32\           0.201   0.263   2.57×10^−6^   1.42\           2.06×10^−14^   1.34\
                                                                                                                                                                                                                                                                 (1.21 - 1.44)                                 (1.23 - 1.65)                  (1.25 - 1.45)

  2q32    rs10931468   A        190.77 - 191.61   *STAT4* (7)                            ●                                   ●                                                                             0.119         0.164                2.55×10^−12^       1.46\           0.120   0.183   2.64×10^−9^   1.64\           2.35×10^−19^   1.50\
                                                                                                                                                                                                                                                                 (1.31 - 1.62)                                 (1.39 - 1.94)                  (1.37 - 1.64)

  3q13    rs2293370    G        120.58 - 120.79   *CD80* (6)                             ●                                   ●                                                                             0.804         0.853                7.70×10^−11^       1.41\           0.809   0.835   0.036         1.19\           2.53×10^−11^   1.35\
                                                                                                                                                                                                                                                                 (1.27 - 1.56)                                 (1.01 - 1.41)                  (1.23 - 1.47)

  4q24    rs7665090    C        103.61 - 104.24   *NFKB1* (7)                                                                                                                                              0.524         0.572                5.33×10^−7^        1.21\           0.513   0.593   5.50×10^−7^   1.38\           4.06×10^−12^   1.26\
                                                                                                                                                                                                                                                                 (1.13 - 1.31)                                 (1.22 - 1.57)                  (1.18 - 1.34)

  5p13    rs860413     A        35.74 - 36.08     *IL7R* (5)                             ●                                   ●                                      ●                                      0.719         0.773                3.09×10^−10^       1.33\           0.729   0.769   4.50×10^−3^   1.24\           1.02×10^−11^   1.30\
                                                                                                                                                                                                                                                                 (1.22 - 1.45)                                 (1.07 - 1.43)                  (1.21 - 1.40)

  7p14    rs6974491    A        37.32 - 37.41     \(0\)                                                                                                                                                    0.170         0.205                3.39×10^−6^        1.25\           0.177   0.215   2.40×10^−3^   1.27\           4.44×10^−8^    1.25\
                                                                                                                                                                                                                                                                 (1.14 - 1.38)                                 (1.09 - 1.49)                  (1.16 - 1.36)

  11q23   rs6421571    C        117.82 - 118.30   *CXCR5* (10)                           ○                                                                                                                 0.809         0.855                3.53×10^−10^       1.40\           0.810   0.847   2.10×10^−3^   1.30\           2.69×10^−12^   1.37\
                                                                                                                                                                                                                                                                 (1.26 - 1.55)                                 (1.10 - 1.55)                  (1.25 - 1.50)

  12p13   rs1800693    C        6.29 - 6.33       *TNFRSF1A* (3)                         ●                                   ●                                                                             0.401         0.452                5.51×10^−8^        1.23\           0.403   0.445   8.70×10^−3^   1.18\           1.80×10^−9^    1.22\
                                                                                                                                                                                                                                                                 (1.14 - 1.33)                                 (1.04 - 1.34)                  (1.14 - 1.30)

  14q24   rs911263     T        67.34 - 67.98     *RAD51L1* (2)                                                                                                                                            0.712         0.764                1.68×10^−9^        1.31\           0.717   0.760   2.30×10^−3^   1.25\           1.76×10^−11^   1.29\
                                                                                                                                                                                                                                                                 (1.20 - 1.43)                                 (1.08 - 1.45)                  (1.20 - 1.39)

  16p13   rs12924729   G        10.92 - 11.22     *CLEC16A* (3)                          ●                                                                                                                 0.679         0.737                7.68×10^−11^       1.32\           0.680   0.718   8.80×10^−3^   1.20\           2.95×10^−12^   1.29\
                                                                                                                                                                                                                                                                 (1.21 - 1.44)                                 (1.05 - 1.38)                  (1.20 - 1.38)

  16q24   rs11117432   G        84.55 - 84.58     \(0\)                                  ○                                                                                                                 0.760         0.808                1.20×10^−6^        1.26\           0.774   0.838   9.52×10^−7^   1.52\           4.66×10^−11^   1.31\
                                                                                                                                                                                                                                                                 (1.15 - 1.39)                                 (1.28 - 1.79)                  (1.21 - 1.43)

  22q13   rs968451     T        37.87 - 38.19     *MAP3K7IP1*\                                                                                                                                             0.194         0.233                4.31×10^−7^        1.27\           0.193   0.237   6.45×10^−4^   1.30\           1.08×10^−9^    1.27\
                                                  (3)                                                                                                                                                                                                            (1.16 - 1.39)                                 (1.12 - 1.51)                  (1.18 - 1.38)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PBC loci that meet genome-wide significance P\<5×10^−8^ in the combined analysis and P\<0.05 in the replication cohort. GWAS and replication cohort data for the replicated SNPs were merged using PLINK.

The putative candidate gene represents the strongest candidate within the region based on available evidence, but does not preclude the existence of other plausible candidate genes within the region. The number of genes is based upon the RefSeq gene track.

Open circles indicate the locus as been previously associated with another autoimmune disease; a filled circle indicates the same candidate gene has also been suggested.

Filled circles indicate the gene was identified by GRAIL as the most plausible functional candidate in the region (P~text~ \< 0.01). GRAIL results are not provided for previously confirmed loci as these were used as seeds in the analysis.

Filled circles indicate a non-synonymous SNP in LD (r^2^ \>0.8) with our top SNP was identified in the candidate gene.

RAF indicates the risk allele frequency.

###### 

Genomic regions reaching genome-wide significance after meta-analysis with [@R7] data.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CHR     SNP         RISK ALLELE   LEFT/RIGHT\       CANDIDATE\                              Discovery sample   [@R7]   Meta-analysis                                                        
                                    REGION (MB)       GENE[a](#TFN11){ref-type="table-fn"}\                                                                                                   
                                                      (Number of genes in\                                                                                                                    
                                                      region)                                                                                                                                 
  ------- ----------- ------------- ----------------- --------------------------------------- ------------------ ------- --------------- ---------------- ------------- ------ -------------- ----------------
  3p24    rs1372072   A             16.82 - 17.13     *PLCL2* (1)                             0.365              0.400   1.38×10^−4^     1.16\            1.52×10^−5^   1.27   2.28×10^−8^    1.20\
                                                                                                                                         (1.08 -- 1.25)                                       (1.12 -- 1.27)

  11q13   rs538147    G             63.60 - 64.04     *RPS6KA4* (20)                          0.606              0.647   1.01×10^−5^     1.19\            7.72×10^−6^   1.28   2.06×10^−10^   1.23\
                                                                                                                                         (1.10 -- 1.29)                                       (1.15 -- 1.31)

  14q32   rs8017161   A             102.54 - 102.68   *TNFAIP2* (3)                           0.396              0.439   4.71×10^−6^     1.20\            4.86×10^−7^   1.31   2.61×10^−13^   1.22\
                                                                                                                                         (1.11 -- 1.29)                                       (1.16 -- 1.27)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The putative candidate gene represents the strongest candidate within the region based on available evidence, but does not preclude the existence of other plausible candidate genes within the region. The number of genes is based upon the RefSeq gene track.

RAF indicates the risk allele frequency.

[@R7] do not provide confidence intervals for the odds ratios (ORs) estimated from their meta-analysis for these SNPs. None of these genomic regions have previously been associated at genome-wide significance with another autoimmune disease. GRAIL failed to identify any strong candidate genes within these regions and no nsSNPs were identified in high LD (r^2^\>0.8) with the most associated SNP at each locus.
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